NCT07447882 Unilateral M1 Anodal tDCS to Enhance Learning in a Gross Movement Videogame Task
| NCT ID | NCT07447882 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Indiana University |
| Condition | Motor Activity |
| Study Type | INTERVENTIONAL |
| Enrollment | 52 participants |
| Start Date | 2025-04-23 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 52 participants in total. It began in 2025-04-23 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Virtual reality as a gaming method is being used more regularly due to its immersive environments and total body playability. A few studies have used VR paired with brain stimulation as a clinical treatment for PTSD (van't Wout-Frank et al. 2024), as well as for regaining movement and cognitive abilities following stroke (Cheng et al. 2024; Lima et al. 2024). While a clinical use for VR and brain stimulation is the ultimate goal, there have still been no basic science investigations studying the efficacy of pairing the two. This investigation will be the first in exploring the connection between VR and brain stimulation as it relates to behavioral improvements (learning the game quicker) and eventually the investigators will begin to study the exact cortical changes that facilitate the accelerated learning. The game "Beat Saber" was chosen because it requires the subjects to move their arm in a large 3-Dimensional space and gives a performance metric after each trial to measure improvement
Eligibility Criteria
Inclusion Criteria: * · Healthy adults between the ages 18-45 * Answer 'no' to questions 2 through 18 on the tDCS checklist as these factors can increase likelihood of adverse events with tDCS (Appendix 1) * No neurological damage, disease, or dysfunction (nerve damage, chronic pain disorders, diabetic neuropathy) that affect the upper limbs. * No significant acute or chronic medical, neurologic, or illness in the patient that, in the judgment of the Principal Investigator, could compromise subject safety, limit the ability to complete the study, and/or compromise the objectives of the study Exclusion Criteria: * · Currently prescribed and taking stimulant medication (Adderall, Ritalin, Vyvanse, etc.) * Consumption of over-the-counter stimulants such as caffeine or nicotine (coffee, soda, supplements, energy drinks, tobacco products, or other nicotine containing products such as gum, vape pens, etc...) 12 hours prior to entering the lab on the day of testing as this can directly affect cortical excitability. If a subject takes any of these substances 12 hours prior to session 1 they will be asked to reschedule for a later date. * Have played the game Beat Saber on a Virtual Reality Headset in the last 12 months.
Contact & Investigator
zachary riley
PRINCIPAL INVESTIGATOR
Indiana University
Frequently Asked Questions
Who can join the NCT07447882 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Motor Activity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07447882 currently recruiting?
Yes, NCT07447882 is actively recruiting participants. Contact the research team at zariley@iu.edu for enrollment information.
Where is the NCT07447882 trial being conducted?
This trial is being conducted at Indianapolis, United States.
Who is sponsoring the NCT07447882 clinical trial?
NCT07447882 is sponsored by Indiana University. The principal investigator is zachary riley at Indiana University. The trial plans to enroll 52 participants.